Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib and sirolimus immunotherapy during analytical treatment interruption in early-treated HIV-1
2025-523118-97-00Phase 2Authorised
- Sponsor
- ANRS
- Start
- Oct 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib and sirolimus in Human immunodeficiency virus infection type 1 (4 arms), sponsored by ANRS. Primary endpoint: Time from treatment interruption to ART resumption. Planned start Oct 2026; status: authorised.
02
Drugs
baricitinibsirolimus
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-523118-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523118-97-00.